ABOUT 17th_ELSF
​> ATTENDEES​
​> INVESTORS​
​> PRESENTERS​
​> EXHIBITORS​
​> SPONSORS​
​> SUPPORTERS​

Sachs Associates would like to say that we have enjoyed hosting you back in-person and virtually and thank those who participated in our Sachs Spring Life Sciences Week, which incorporated the 5th Annual European HealthTech CEO Forum (Sachs_EHTF) and the 17th Annual European Life Sciences CEO Forum (Sachs_ELSF).  A special thank you goes to the excellent line-up of sponsors, chairs, panellists, exhibitors and presenters who made such a broad and interesting programme possible and to those who participated in-person and during the virtual week.

The Life Sciences Week has proven to be successful in supporting our community with over 500 people from 30 countries registered and over 2000 in-person & online meetings completed.  

Publicly available recordings of the sessions and presentations which took place during the event will be added in a couple of weeks on SachsTV YouTube channel.

We are looking forward to welcoming you again in our future events!

Sponsors Included:

Exhibitor Included:

Confirmed Presenters Included:

Biotech Rising Stars Included:

Confirmed Keynote Speakers Included:

• "Opportunities for European Life Sciences & Healthcare Companies in the Hong Kong Capital Markets" by Chris Roberts, Head of EMEA Issuer Services, Hong Kong Exchanges and Clearing Limited
• “Overcoming Obesity—The Discovery of Multi-Receptor Drugs” by  Matthias Tschöp , Chief Executive Officer & Chief Scientific Officer,  Helmholtz Munich
  
• "AI in the Life Sciences: Hallucinations or Innovations?" by Liesbeth Ceelen, CEO, Biolizard SA

Confirmed Chairs & Speakers Included:

• Alessandra Polara, Senior Director, Global BD, F. Hoffmann-La Roche AG
• Allan Marchington, Managing Director, Head of Life Sciences, Intermediate Capital Group PLC
• Andreas Jurgeit, Partner, Gimv
• Andreas Pahl, CEO, Heidelberg Pharma AG
• Andreas Wallnoefer, Partner, Jeito Capital
• Anna Lisa Picciolo-Lehrke, Head Business Development Neurology, UCB Pharma
• Antoine Boulanger, Principal, Forbion
• Apollon Papadimitriou, CEO, iOmx Therapeutics AG
• Aram Mangasarian, CEO, TME Pharma
• Astrid Maria Dahl, COO & Head of Europe, Innovent Biologics
• Asun Monfort, Investment Advisor, HBM Partners AG
• Bauke Anninga, Investment Director, M Ventures
• Benjamin Thomas, Senior Vice President - Operations, Oxford BioTherapeutics Ltd.
• Birgit Steckel-Hamann, Sr. Director Diabetes External Innovation & Head of Public Private Partnerships Europe, Eli Lilly and Company
• Carlos Buesa, Founder & CEO, Oryzon Genomics, S.A.
• Chris Roberts, Head of EMEA Issuer Services, Hong Kong Exchanges and Clearing Limited
• ​Christian Thomsen, Global Head, CNS BD&L, Boehringer Ingelheim International GmbH
• Dani Bach, Partner, +ND Capital
• Daniel Parera, Partner, Kurma Partners
• David Colpman, Director, Alpina Life Science Advisors
• Diana Saraceni, Co-Founder & General Partner, Panakès Partners SGR SpA
• Donald Xu, Managing Partner, Lynx Financial Hong Kong Ltd.
• Dragan Grabulovski, Acting CEO, Araris Biotech AG
• Edouard Caram, Sr Director, Global Partnership Rare Diseases & Neurosciences, Ipsen
• Emin Fadillioglu, CEO, Eczacibasi Pharmaceutical and Industrial Investment Co.
• Eric Halioua, President & CEO, PDC*line Pharma SA
• Esteban Pombo-Villar, CTO, TargImmune Therapeutics AG
• Evonne Sepsis, Managing Director, ESC Advisors
• Francois Ravenelle, Founder & CEO, Inversago Pharma Inc.
• François Thomas, Operating Partner, Quadrille Capital
• Georgia Frost, Senior Associate, Dementia Discovery Fund - SV Health Investors LLP
• Göran Forsberg, CEO, Cantargia AB
• Helen Chen, Global Sector Co-Head, Healthcare & Life Sciences | Greater China Managing Partner, L.E.K. Consulting
• Jesus Baena, BD&L Transactions Director, Novartis AG
• Joachim Vogt, Director Search & Evaluation International, AbbVie, Inc.
• Jonathan Tobin, Partner, Brandon Capital
• Josua Jordi, Co-Founder & CEO, EraCal Therapeutics Ltd.
• Katya Smirnyagina, Senior Partner, Oxford Science Enterprises
• Kelly Curtin, Managing Director, Stifel
• Khatereh Ahmadi, Head of Search & Evaluation Business Development, Europe & Middle East, MSD
• Klaus Breiner, Managing Partner, Pureos Bioventures
• Klaus Dugi, CEO, Vandria SA
• Konstantin Petropoulos, CBO & Managing Director, Secarna Pharmaceuticals GmbH & Co. KG
• Lubor Gaal, CFO & Head of BD & Alliance Management, Circio Holding ASA
• Lynn Durham, Founder & CEO, STALICLA SA
• Marc Ditmarsch, Chief Development Officer, NewAmsterdam Pharma
• Marc Robillard, CEO, Tagworks Pharmaceuticals BV
• Marie Leblanc, Executive Director, Global Head of Account Management, Cell & Gene Technologies, Lonza AG
• Mark Rayner, Managing Partner, GOLDTRACK Ventures GmbH
• Michael Altorfer, CEO, Swiss Biotech Association
• Michael Hübner, Director Early Innovation Partnering, Johnson & Johnson Innovation LLC
• Nathalie ter Wengel, European Lead, Worldwide Business Development, Pfizer, Inc.
• Naveed Siddiqi, Senior Partner, Novo Holdings A/S
• Nigel Sheail, Venture Partner, Versant Ventures
• Olav Zilian, Senior Equity Analyst - Healthcare, Pictet & Cie SA
• Paul Hermant, Partner, Bird & Bird LLP
• Peter Braun, CEO, TargImmune Therapeutics AG
• Philip Larsen, CEO, SixPeaks Bio
• Rianne Ellenbroek, Principal, BioGeneration Ventures
• Richard Ward, Executive Director, Search & Evaluation, AstraZeneca
• Sandra von Meier, Head Business Development & Licensing, Debiopharm International SA
• Sarah Holland, President of Swiss Healthcare Licensing Group & CBO, Cureteq AG
• Sascha Berger, Partner, TVM Capital Life Science
• Simon Chandler, CEO, Rinri Therapeutics Ltd.
• Søren Møller, Managing Partner, Novo Holdings A/S
• Stacy Lindborg, Co-CEO, Brainstorm Cell Therapeutics, Inc.
• Stefano Portolano, CEO, Azafaros Switzerland AG
• Stephan Lensky, COO & CBO, EpimAb Biotherapeutics
• Stephanie Léouzon, Managing Director, Stifel
• Stephen Doyle, Chief Business Officer, Aslan Pharmaceuticals
• Stephen Myatt, CEO, Macomics Ltd.
• Susan Hill, CEO, Mestag Therapeutics Ltd.
• Tamas Schweighoffer, Co-Founding Partner, Forty51 Ventures AG
• Tom Shepherd, CEO, Captor Therapeutics S.A.
• Ulrich Wendt, Global Head Business Development Immunology & Inflammation, Sanofi
• Victoria English, Co-Founder & Editor of Evernow Publishing Ltd, publisher, MedNous
  

To learn more about presenting, exhibition or sponsorship opportunities, please fill in registration form or contact us at [email protected] or by phone + 44 (0)203 463 4890.

Silver Sponsor:

---

Bronze Sponsors:

---

Contributing Sponsor:

---

Silver Sponsor in 2023:

---

Supporters:

---

Financial, Advisory & Investors Included:

+ND Capital
AAA Family Office
AdBio Partners
AFK & Partners Asset Management LLC
Aglaia Oncology Funds
Aliath Bioventures
Amplitude Ventures
ARVE Capital GmbH
Bergmann zur Hausen & Cie. GmbH
BioMedPartners AG
BioMedVC AG
Bioqube Ventures
BlackRock
bmp Ventures AG
BOHE Angel Fund
Boostrap Europe
Bpifrance
Brandon Capital
Breslin AG
Business Angels Switzerland
CARMA FUND Management GmbH
Cathay Health
CEBINA Bridge Capital
Convergence Partners
DeBere Capital Partners
Debiopharm International S.A.
Delin Ventures Ltd.
Dementia Discovery Fund - SV Health Investors LLP
Digital Networks Plc. S.r.l.
ESC Advisors
Evoleen
Forbion
Forty51 Ventures
Forty51 Ventures AG
Fraser Finance
FutuRx
GIBF
Gimv
Global Life Science Ventures GmbH
H Tree Capital
Hadean Ventures
HBM Partners AG
High-Tech Gründerfonds Management GmbH
Indaco Bio Fund
Innovestor Life Science Ltd.
Intermediate Capital Group PLC
IPF Partners
Jeito Capital
Johnston Associates, Inc.
JP Morgan
Kinled Holding Limited

To View All - Click Here